Fatemeh Mirzayeh Fashami
Expertise:
Fatemeh is a Research Associate in the Value & Evidence Division at EVERSANA, with experience in evidence synthesis, value communications, and economic modelling.
Fatemeh holds an MSc in Health Research Methodology in the HTA stream from McMaster University, where she gained experience with meta-analyses, systematic literature reviews, and health economic modelling.
Along with her pharmacy background, she has experience in article screening, data extraction, analysis, cost-effectiveness modelling, and CADTH economic submissions. At CRG-EVERSANA, Fatemeh has been involved in literature reviews and HTA submissions.
Articles by Fatemeh Mirzayeh Fashami
A Review of Indirect Treatment Comparisons (ITCs) in Regulatory Approval, Reimbursement and Pricing Recommendations for Oncology Drugs
The use of indirect treatment comparisons (ITCs) has increased significantly in recent years, particularly in the assessment of oncology and rare diseases where direct head-to-head trials may be impractical or unavailable, with numerous oncology and orphan drug submissions incorporating ITCs to support regulatory decisions and health technology assessment (HTA) recommendations. The Value & Evidence team at EVERSANA (Krista Tantakoun, Christopher Olsen, Fatemeh Mirzayeh Fashami, Imtiaz Samjoo and Chris Cameron), in collaboration with Dr. Brian Hutton, professors at Kyoto University and Yokohama City University School of Medicine in Japan, and colleagues at Janssen Pharmaceutical, critically reviewed and synthesized assessment documents for oncology drug submissions that included ITCs from various regulatory bodies […]
A Review of Worldwide Indirect Treatment Comparison (ITC) Guidelines and Best Practices
Considering the challenges of conducting head-to-head clinical trials, indirect treatment comparisons (ITCs) offer valuable insights into clinical effectiveness that reflect current and local practices. These insights can help regulators and reimbursement agencies make better-informed decisions, thereby facilitating patient access to novel treatments. Recent methodological advancements in ITCs have led to the release of regional, national and global guidelines outlining jurisdiction-specific methodology and reporting recommendations and/or best practices. The Value & Evidence team at EVERSANA (Krista Tantakoun, Christopher Olsen, Fatemeh Mirzayeh Fashami, Imtiaz Samjoo and Chris Cameron), in collaboration with Dr. Brian Hutton, professors at Kyoto University and Yokohama City University School of Medicine in Japan, and colleagues at Janssen Pharmaceutical, […]